In short
Clinical trials are investigating Zanamivir in very young patients with confirmed complicated influenza infection. The study data focus on safety, tolerability, and how the body handles treatment in neonates and infants under 6 months of age. These trials also explore early clinical outcomes in hospitalized children.
Key points
- Zanamivir clinical trial data here focus on hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The study is a Phase 2 interventional trial and is completed. Researchers looked at safety, tolerability, and pharmacokinetics, which means how the body handles the treatment. The main measurements included AUC, Cmax, clearance, and terminal half-life. The trial also explored clinical outcomes during treatment with intravenous Zanamivir. Only 11 participants were enrolled.
Trial overview
This article covers one interventional study of Zanamivir in very young children with influenza. The trial was completed and enrolled 11 participants.
The study focused on hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection.
Who participated
The target population was neonates, meaning babies in the first 28 days of life, and infants under 6 months of age.
All participants had confirmed complicated influenza infection and were hospitalized, so this was a very specific and medically fragile group.
What was studied
Researchers studied intravenous Zanamivir, given as Dectova 10 mg/mL solution for infusion in the trial record.
The main goal was to evaluate single-dose and multiple-dose pharmacokinetics, which means how the treatment moves through the body over time.
The trial also assessed safety and tolerability, meaning whether the treatment could be given without unacceptable problems and how well the children could handle it.
In addition, the study explored clinical outcomes during treatment, so the researchers looked beyond blood measurements to see what happened clinically in these patients.
Outcomes measured
The primary outcomes were AUC, Cmax, clearance, and terminal half-life.
AUC means area under the concentration-time curve and shows total exposure to the treatment in the blood.
Cmax is the highest blood level reached after treatment.
Clearance shows how quickly the body removes the treatment, and terminal half-life shows how long it takes the blood level to drop by half near the end of the process.
Study design and phase
The study was a Phase 2 trial, which is often used to gather more information about safety and early effectiveness in a defined patient group.
It was also an open-label, single-arm study, meaning everyone knew what treatment was being given and there was no comparison group listed in the trial record.
Because the trial is completed, the planned research steps have already been finished.